Despite a rather strict symptom definition (small joint arthralgia, duration <12 months, and rheumatologist’s suspicion of progression to arthritis), 2-year progression to arthritis was only 10% among patients negative for anti-CCP2, RF, and anti-CarP. This evidence concerns the gene AGBL2 and arthritic joint disease.